Status:
COMPLETED
The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Gastro-enteropancreatic Neuroendocrine Tumor
Secondary Malignant Neoplasm of Liver
Eligibility:
All Genders
18+ years
Brief Summary
Imaging with CT (Computed Tomography) or MRI (Magnetic Resonance Imaging) is normally used to see how tumors respond to treatment. If tumors shrink after therapy, doctors continue with the same treatm...
Eligibility Criteria
Inclusion
- Histopathologic evidence of well differentiated neuroendocrine tumor of gastroenteropancreatic origin
- Evidence of metastatic disease of at least 2.0 cm in the liver by MRI or CT imaging.
- Patient ≥18 years of age on the day of signing informed consent.
Exclusion
- Any contraindication to MRI based on departmental MR questionnaire
- Inability to cooperate for an MR exam
- Patient has a history of a second active malignancy with evidence of metastases. Patients with a history of resected prior malignancy or one that would not interfere with the MRI results is allowed.
- Patient has known psychiatric or substance abuse disorders that would, in the opinion of the treating investigator, interfere with cooperation with the requirements of the trial.
Key Trial Info
Start Date :
August 23 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 19 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01423734
Start Date
August 23 2011
End Date
January 19 2023
Last Update
January 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065